European principles of inhibitor management in patients with haemophilia: implications of new treatment options
Language English Country Great Britain, England Media electronic
Document type Letter
PubMed
32831110
PubMed Central
PMC7444030
DOI
10.1186/s13023-020-01511-8
PII: 10.1186/s13023-020-01511-8
Knihovny.cz E-resources
- Keywords
- Bypassing agents, Emicizumab, Factor IX, Factor VIII, Guidelines, Haemophilia, Immune tolerance, Inhibitors,
- MeSH
- Factor IX MeSH
- Factor VIII MeSH
- Hemophilia A * drug therapy MeSH
- Medicine * MeSH
- Humans MeSH
- Sex Chromosome Disorders * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Names of Substances
- Factor IX MeSH
- Factor VIII MeSH
Canterbury Christ Church University Kent UK
Children's University Hospital and Masaryk University Brno Czech Republic
European Haemophilia Consortium Brussels Belgium
See more in PubMed
PLF G, Hermans C, O’Mahony B, de KP BM, Batorova A, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis. 2018;13(1):66. doi: 10.1186/s13023-018-0800-z. PubMed DOI PMC
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017;377(9):809–818. doi: 10.1056/NEJMoa1703068. PubMed DOI
Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jimenez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia a with inhibitors. Blood. 2019;134(24):2127–2138. doi: 10.1182/blood.2019001869. PubMed DOI PMC
Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia a with and without inhibitors. Haemophilia. 2020;26(1):41–46. doi: 10.1111/hae.13877. PubMed DOI
Page D. Parent testimonial: a caregiver whose son with inhibitors has been receiving emicizumab. Transfus Apher Sci. 2019;58:5. doi: 10.1016/j.transci.2018.12.008. PubMed DOI
Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, et al. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. J Thromb Haemost. 2018;16(10):1984–1993. doi: 10.1111/jth.14247. PubMed DOI
Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. A molecular revolution in the treatment of hemophilia. Mol Ther. 2019;28(4):997. doi: 10.1016/j.ymthe.2019.11.006. PubMed DOI PMC
The Hemophilia Inhibitor Prevention Trial. https://www.clinicaltrials.gov/ct2/show/NCT04303559. 22-7-2020.
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7). https://www.clinicaltrials.gov/ct2/show/NCT04431726?term=emicizumab&draw=2&rank=6 . 22-7-0020.
Pierce GF, Hart DP, Kaczmarek R. Safety and efficacy of emicizumab and other novel agents in newborns and infants. Haemophilia. 2019;25(5):e334–e335. doi: 10.1111/hae.13822. PubMed DOI
Jenkins PV, Bowyer A, Burgess C, Gray E, Kitchen S. Murphy P et al. Haemophilia: Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline; 2019. p. 151. PubMed
Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, et al. Management of bleeding and invasive procedures in haemophilia a patients with inhibitor treated with emicizumab (Hemlibra((R)) ): proposals from the French network on inherited bleeding disorders (MHEMO), the French reference Centre on Haemophilia, in collaboration with the French working group on perioperative Haemostasis (GIHP) Haemophilia. 2019;25(5):731–737. doi: 10.1111/hae.13817. PubMed DOI
Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, et al. Emergency management in patients with haemophilia a and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2019;18:1–8. PubMed PMC
Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, et al. The changing face of immune tolerance induction in haemophilia a with the advent of emicizumab. Haemophilia. 2019;25(4):676–684. PubMed PMC
Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio RF., Jr Immune tolerance induction in paediatric patients with haemophilia a and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25(5):789–796. doi: 10.1111/hae.13819. PubMed DOI
The Hemophilia Inhibitor Eradication Trial. https://clinicaltrials.gov/ct2/show/NCT04303572.
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1). https://www.clinicaltrials.gov/ct2/show/NCT02622321.
Kajiwara M, Shima M, Yoshioka A. Two haemophilia patients with inhibitors who became ambulatory after physiotherapy under haemostatic cover with bypassing agents. Haemophilia. 2013;19(5):e301–e304. doi: 10.1111/hae.12179. PubMed DOI
